MX2019014876A - Compuestos heteroaromaticos como inhibidores de vanina. - Google Patents

Compuestos heteroaromaticos como inhibidores de vanina.

Info

Publication number
MX2019014876A
MX2019014876A MX2019014876A MX2019014876A MX2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A
Authority
MX
Mexico
Prior art keywords
heteroaromatic compounds
compounds
vanin
inhibitors
vanin inhibitors
Prior art date
Application number
MX2019014876A
Other languages
English (en)
Inventor
Bosanac Todd
Nicholas Cook Brian
Todd Disalvo Darren
j burke Michael
Martin Kirrane Thomas Jr
Shen Yue
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019014876A publication Critical patent/MX2019014876A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención abarca los compuestos de la Fórmula (I) (ver Fórmula) en donde los grupos A y B se definen en la presente, que son adecuados para el tratamiento de enfermedades relacionadas con vanina, y los procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso.
MX2019014876A 2017-06-12 2018-06-08 Compuestos heteroaromaticos como inhibidores de vanina. MX2019014876A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518106P 2017-06-12 2017-06-12
PCT/EP2018/065140 WO2018228934A1 (en) 2017-06-12 2018-06-08 Heteroaromatic compounds as vanin inhibitors

Publications (1)

Publication Number Publication Date
MX2019014876A true MX2019014876A (es) 2020-02-13

Family

ID=62631060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014876A MX2019014876A (es) 2017-06-12 2018-06-08 Compuestos heteroaromaticos como inhibidores de vanina.

Country Status (23)

Country Link
US (2) US10364255B2 (es)
EP (1) EP3638680B1 (es)
JP (1) JP6880243B2 (es)
KR (1) KR102607934B1 (es)
CN (1) CN110770242B (es)
AR (1) AR112086A1 (es)
AU (1) AU2018285131B2 (es)
BR (1) BR112019021703A2 (es)
CA (1) CA3066946A1 (es)
CL (1) CL2019003515A1 (es)
CO (1) CO2019013823A2 (es)
DK (1) DK3638680T3 (es)
EA (1) EA039223B1 (es)
ES (1) ES2927021T3 (es)
HU (1) HUE060597T2 (es)
IL (1) IL271104B (es)
MA (1) MA49374A (es)
MX (1) MX2019014876A (es)
PE (1) PE20200340A1 (es)
PH (1) PH12019502693A1 (es)
PL (1) PL3638680T3 (es)
TW (1) TW201920196A (es)
WO (1) WO2018228934A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2927021T3 (es) * 2017-06-12 2022-11-02 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina
EP3837263A1 (en) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
DK3844161T3 (da) * 2018-08-28 2022-12-12 Boehringer Ingelheim Int Heteroaromatiske forbindelser som vanininhibitorer.
AR117229A1 (es) 2018-12-03 2021-07-21 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004018811D1 (de) * 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EP3303303A1 (en) * 2015-05-29 2018-04-11 Pfizer Inc Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
AU2017296338A1 (en) * 2016-07-14 2019-01-03 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
ES2927021T3 (es) * 2017-06-12 2022-11-02 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina

Also Published As

Publication number Publication date
EP3638680A1 (en) 2020-04-22
US10364255B2 (en) 2019-07-30
PE20200340A1 (es) 2020-02-14
CA3066946A1 (en) 2018-12-20
IL271104B (en) 2022-03-01
CN110770242A (zh) 2020-02-07
CN110770242B (zh) 2022-08-19
PL3638680T3 (pl) 2022-12-19
AU2018285131B2 (en) 2021-11-11
WO2018228934A1 (en) 2018-12-20
AR112086A1 (es) 2019-09-18
DK3638680T3 (da) 2022-09-05
KR102607934B1 (ko) 2023-12-01
EA039223B1 (ru) 2021-12-20
BR112019021703A2 (pt) 2020-05-12
CL2019003515A1 (es) 2020-06-19
TW201920196A (zh) 2019-06-01
PH12019502693A1 (en) 2020-07-13
AU2018285131A1 (en) 2019-10-31
US20190263828A1 (en) 2019-08-29
MA49374A (fr) 2021-04-21
EP3638680B1 (en) 2022-08-10
ES2927021T3 (es) 2022-11-02
EA202090014A1 (ru) 2020-05-12
CO2019013823A2 (es) 2020-01-17
HUE060597T2 (hu) 2023-04-28
US20180354968A1 (en) 2018-12-13
JP2020522517A (ja) 2020-07-30
JP6880243B2 (ja) 2021-06-02
IL271104A (en) 2020-01-30
KR20200013718A (ko) 2020-02-07

Similar Documents

Publication Publication Date Title
MY197440A (en) Heteroamatic compounds as btk inhibitors
PH12020500252A1 (en) Compounds as modulators of ror gamma
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
SA515360007B1 (ar) مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk)
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2017014035A (es) Formas solidas novedosas.
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
PH12016502568B1 (en) Novel heterocyclic compound
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.